Cardiac Autonomic Neuropathy in Diabetes Mellitus

Shruti Agashe, Steven Petak

Research output: Contribution to journalReview articlepeer-review

72 Scopus citations


Cardiovascular autonomic neuropathy (CAN) is a severely debilitating yet underdiagnosed condition in patients with diabetes. The prevalence can range from 2.5% (based on the primary prevention cohort in the Diabetes Control and Complications Trial) to as high as 90% of patients with type 1 diabetes. Clinical manifestations range from orthostasis to myocardial infarction. The diagnosis is made using multiple autonomic function tests to assess both sympathetic and parasympathetic function. The pathophysiology of CAN is complex, likely multifactorial, and not completely understood. Treatment is limited to symptomatic control of orthostatic hypotension, which is a late complication, and current strategies to reverse CAN are limited. This review explores the epidemiology, pathophysiology, clinical manifestations, diagnosis, and complications of CAN as well as current treatment options.

Original languageEnglish (US)
Pages (from-to)251-256
Number of pages6
JournalMethodist DeBakey cardiovascular journal
Issue number4
StatePublished - Oct 1 2018


  • CARTs
  • DCCT study
  • EDIC study
  • EURODIAB study
  • Toronto Consensus Panel
  • Valsalva
  • cardiac autonomic neuropathy
  • cardiac autonomic reflex tests
  • cardiovagal
  • diabetes
  • diabetic neuropathy
  • exercise intolerance
  • glycosylation
  • heart rate variability
  • hyperglycemia
  • microvascular complications
  • orthostatic hypotension
  • parasympathetic
  • perioperative mortality
  • reactive oxygen species
  • resting tachycardia
  • silent ischemia
  • sympathetic

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Cardiac Autonomic Neuropathy in Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this